uniQure CompletesEnrollment In First Cohort Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease
uniQure CompletesEnrollment In First Cohort Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington's disease. The Company also announced plans to begin an open-label clinical trial of AMT-130 in Europe later this year.
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington's disease. The Company also announced plans to begin an open-label clinical trial of AMT-130 in Europe later this year.
亞洲網加利福尼亞州聖何塞2月16日電領先的基因治療公司UnQure N.V.(納斯達克市場代碼：Qure)今天宣佈，AMT-130治療早期亨廷頓病的隨機、雙盲、I/II期臨牀試驗的第一劑患者招募工作已經完成。UnQure N.V.是一家為有嚴重醫療需求的患者推進變革性療法的領先基因治療公司。該公司還宣佈計劃今年晚些時候在歐洲開始AMT-130的開放標籤臨牀試驗。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧